NEWForm 8-K - Current report - Item 7.01 Item 9.01
8-K
InMed Pharmaceuticals Announces Annual Meeting Results, Approval of Corporate Name Change to Mentari Therapeutics, and 1-for-10 Share Consolidation
8-K
InMed Pharmaceuticals Announces Annual Meeting Results, Approval of Corporate Name Change to Mentari Therapeutics, and Completion of 1-for-10 Share Consolidatio
8-K
InMed Reports First Quarter Fiscal 2027 Financial Results and Mentari Merger Updates
8-K
InMed Pharmaceuticals Receives Nasdaq Minimum Stockholders’ Equity Notification and Anticipates Resolving Deficit via Pending Merger with Mentari
8-K
Mentari Therapeutics Announces $200 Million Private Placement to Support Migraine Pipeline
Prospectus
TYPE
HEADLINE
FILED AT
425
Form 425 - Prospectuses and communications, business combinations
424B3
UPDATE TO PRIOR PROSPECTUS
425
Form 425 - Prospectuses and communications, business combinations
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]
425
Form 425 - Prospectuses and communications, business combinations
425
Form 425 - Prospectuses and communications, business combinations
